Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ME

23andMe Holding Co

Sep 17 • 04:00PM ET

0.3412

Dollar change -0.0010
Percentage change -0.29	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA VHT PRFZ ONEQ FESM ITOT BIB SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	41.12%	Shs Outstand	323.39M	Perf Week	13.81%
Market Cap	172.65M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-0.07%	Shs Float	297.95M	Perf Month	-0.50%
Income	-631.48M	PEG	-	EPS next Q	-0.16	Inst Own	14.75%	Short Float	7.07%	Perf Quarter	-14.70%
Sales	199.19M	P/S	0.87	EPS this Y	55.04%	Inst Trans	6.79%	Short Ratio	6.56	Perf Half Y	-27.54%
Book/sh	0.28	P/B	1.20	EPS next Y	15.48%	ROA	-101.91%	Short Interest	21.08M	Perf Year	-68.98%
Cash/sh	0.34	P/C	1.01	EPS next 5Y	-	ROE	-154.21%	52W Range	0.29 - 1.10	Perf YTD	-62.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.81%	ROI	-302.59%	52W High	-68.98%	Beta	1.17
Dividend TTM	-	Quick Ratio	1.39	Sales past 5Y	-22.63%	Gross Margin	31.16%	52W Low	17.66%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	1.49	EPS Y/Y TTM	-82.32%	Oper. Margin	-144.72%	RSI (14)	52.22	Volatility	5.40% 6.18%
Employees	582	Debt/Eq	0.52	Sales Y/Y TTM	-32.67%	Profit Margin	-317.03%	Recom	2.00	Target Price	0.42
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	38.14%	Payout	-	Rel Volume	0.46	Prev Close	0.34
Sales Surprise	-24.88%	EPS Surprise	36.31%	Sales Q/Q	-33.60%	Earnings	Aug 08 AMC	Avg Volume	3.21M	Price	0.34
SMA20	6.52%	SMA50	-9.94%	SMA200	-37.82%	Trades		Volume	1,490,718	Change	-0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-22	Initiated	Berenberg	Buy	$7
Sep-22-22	Initiated	Cowen	Outperform	$6
Nov-15-21	Downgrade	Citigroup	Buy → Neutral	$12 → $13
Aug-17-21	Initiated	Credit Suisse	Outperform	$13
Jul-12-21	Initiated	Citigroup	Buy	$14

Today 03:51AM	Landmark Fed decision in focus, futures edge higher - what's moving markets (Investing.com)
01:29AM	23andMe Board Resigns in New Blow to DNA-Testing Company (The Wall Street Journal)
Sep-17-24 05:28PM	23andMe independent directors quit board over unsatisfactory buyout plan from CEO (Reuters)
04:26PM	Independent Directors of 23andMe Resign from Board (GlobeNewswire)
Sep-15-24 03:00AM	23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial (GlobeNewswire)
03:00AM	Loading…
03:00AM	23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study (GlobeNewswire)
Sep-13-24 12:41PM	23andMe settles data breach lawsuit for $30 million (Reuters)
Sep-12-24 04:05PM	One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations (GlobeNewswire) +6.93%
Sep-11-24 06:06PM	23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows (Reuters)
Sep-03-24 07:30AM	23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024 (GlobeNewswire)
Aug-28-24 07:30AM	Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program (GlobeNewswire)
Aug-08-24 09:56PM	ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025 (InvestorPlace)
04:05PM	23andMe Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Aug-02-24 08:28AM	23andMe board rejects CEO Wojcickis take-private proposal (MedTech Dive)
08:25AM	Genetic testing firm 23andMe rejects CEO's take-private offer (Reuters)
08:00AM	Loading…
08:00AM	23andMe Special Committee responds to CEO's take-private proposal (GlobeNewswire)
Aug-01-24 08:01AM	23andMe CEO proposes to take company private (MedTech Dive)
08:00AM	23andMe Announces CEO's Take-Private Proposal (GlobeNewswire)
Jul-31-24 06:52PM	23andMe CEO Wojcicki makes offer to take the firm private, filing shows (Reuters)
Jul-25-24 04:45PM	23andMe to Report Q1 FY2025 Financial Results (GlobeNewswire)
07:30AM	Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research (GlobeNewswire)
Jul-24-24 10:57AM	The 3 Best Personalized Nutrition Stocks to Buy Now (InvestorPlace)
Jul-11-24 06:45AM	3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts (InvestorPlace)
Jul-01-24 10:23AM	23andMe and Nightingale partner to pilot blood-based risk detection panel (Medical Device Network)
Jun-28-24 07:00AM	23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel (GlobeNewswire) -7.58%
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
Jun-05-24 07:00AM	23andMe Launches New Genetic Report on Bipolar Disorder (GlobeNewswire)
Jun-04-24 12:48PM	Why 23andMe Stock Tumbled 10% on Tuesday (Motley Fool) -15.27%
07:00AM	23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community (GlobeNewswire)
Jun-03-24 08:00AM	23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting (GlobeNewswire)
08:00AM	Loading…
May-29-24 08:00AM	Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history (GlobeNewswire) +11.95%
May-24-24 08:40AM	Q4 2024 23andMe Holding Co. Earnings Call (Thomson Reuters StreetEvents)
08:04AM	23andMe Holding Co. (NASDAQ:ME) Q4 2024 Earnings Call Transcript (Insider Monkey)
May-23-24 08:53PM	ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024 (InvestorPlace)
04:05PM	23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results (GlobeNewswire)
May-14-24 03:59PM	Sector Update: Health Care Stocks Rise in Late Afternoon Trading (MT Newswires) +15.46%
02:03PM	Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading (MT Newswires)
12:08PM	23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication (MT Newswires)
09:15AM	Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe (ACCESSWIRE)
07:00AM	Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals (GlobeNewswire)
May-10-24 04:36PM	Struggling 23andMe Granted Extension to Revive Stock Price (Bloomberg) +6.35%
May-09-24 04:50PM	23andMe to Report Q4 and Full Year FY2024 Financial Results (GlobeNewswire) +5.66%
Apr-25-24 09:44PM	7 Best Sites Like Ancestry.com to Research Your Family History (Insider Monkey)
Apr-24-24 04:05PM	23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.39%
Apr-23-24 05:21AM	This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next (Motley Fool) +7.23%
Apr-19-24 03:43PM	23andMe CEO Anne Wojcicki Says Shes Weighing Buyout Bid (Barrons.com)
Apr-18-24 11:09AM	Stocks to Watch Thursday: TSMC, Netflix, Nvidia, Tesla (The Wall Street Journal) +41.91%
10:36AM	23andMe Stock Jumps on News of Plans to Take It Private (The Wall Street Journal)
10:01AM	23andMe CEO Anne Wojcicki Plans to Take Company Private (The Wall Street Journal)
10:00AM	23andMe Jumps as CEO Floats Taking DNA Tester Private (Bloomberg)
08:00AM	23andMe announces CEO's intention to pursue a potential take-private (GlobeNewswire)
06:35AM	23andMe CEO plans to take company private (MedTech Dive)
Apr-17-24 11:12PM	23andMe CEO Wojcicki considering taking firm private, filing shows (Reuters) -8.69%
Apr-05-24 04:05PM	23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Mar-24-24 03:23AM	Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead? (Motley Fool)
Mar-20-24 07:30AM	23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 (GlobeNewswire)
Mar-19-24 08:00AM	23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago (GlobeNewswire)
Mar-06-24 07:30AM	23andMe Launches New Genetic Reports on Common Forms of Cancer (GlobeNewswire) +5.90%
Mar-05-24 04:30PM	23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) -6.86%
Feb-23-24 05:15AM	20 Most Valuable Digital Health Companies In The US (Insider Monkey) -5.83%
Feb-13-24 09:53AM	Is 23andMe Stock a Smart Buy Right Now? (Motley Fool)
Feb-08-24 01:13PM	23andMe Stock Slides After DNA-Testing Company's Disappointing Results (The Wall Street Journal) -13.05%
08:59AM	23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Call Transcript (Insider Monkey)
08:27AM	Q3 2024 23andMe Holding Co. Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 09:44PM	How 23AndMe Went From a $6 Billion Valuation to a Penny Stock (WSJ)
06:55PM	23andMe Mulls Possible Split, Shares Fall After Disappointing Results (The Wall Street Journal)
05:42PM	Struggling 23andMe Is Exploring Splitting the DNA Company in Two (Bloomberg)
04:54PM	23andMe Holding Co (ME) Faces Revenue Decline and Net Loss in Q3 FY24 (GuruFocus.com)
04:01PM	23andMe Reports Third Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Feb-05-24 03:23PM	SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy (Benzinga) -5.26%
07:35AM	Main Street is still investing like its 2023 (CNN Business)
Feb-02-24 04:30PM	23andMe is low on cash and its stock is worth pennies. The CEO wants another chance (CNN Business)
Jan-31-24 11:10AM	Lawsuits for Consumers with Accounts at 23andMe Holding Co. (NASDAQ: ME) in connection with Data Breach announced by the Shareholders Foundation (GlobeNewswire)
07:30AM	23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 (GlobeNewswire)
05:30AM	23andMes Fall From $6 Billion to Nearly $0 (The Wall Street Journal)
Jan-30-24 10:12PM	23andMe Launches Month-Long Initiative to Amplify ARRAY's Seat16 Program for Acclaimed Film ORIGIN by Ava DuVernay (GlobeNewswire)
Jan-24-24 04:05PM	23andMe to Report FY2024 Third Quarter Financial Results (GlobeNewswire) +6.00%
Jan-21-24 06:11AM	The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them (Motley Fool)
Jan-03-24 04:30PM	23andMe blames users for data breach, citing recycled passwords (Fox Business) -8.04%
Dec-26-23 07:12PM	5 Most Promising Small-Cap Stocks According to Analysts (Insider Monkey)
Dec-19-23 08:00AM	23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts (GlobeNewswire) +10.49%
Dec-13-23 04:00AM	The Danger in Genetic-Data Breaches: You Cant Change Your DNA. (Barrons.com)
Dec-08-23 04:52PM	23andMe makes a controversial move that customers won't like (TheStreet.com)
Dec-07-23 11:04AM	Cyberattacks surge in 2023, as millions fall victim to ransomware: Report (Yahoo Finance) -9.94%
Dec-06-23 05:14PM	23andMe isn't the only DNA testing company that faced a data leak (TheStreet.com)
11:55AM	23andMe data leak reveals dangers of DNA testing kits (TheStreet.com)
Dec-05-23 09:00PM	23andMe Hack Is a Wake-Up Call for Your Password Habits (The Wall Street Journal)
06:27PM	Starbucks, 23andMe, JetBlue and Spirit: Trending tickers (Yahoo Finance Video)
01:30PM	Hackers access profiles of nearly 7 million 23andMe customers (CNN Business)
01:26AM	PRESS DIGEST-New York Times business news - Dec 5 (Reuters)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-10-23 12:13PM	23andMe Holding Co. (NASDAQ:ME) Q2 2024 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	23andMe Reports Second Quarter Fiscal 2024 Financial Results (GlobeNewswire) -21.96%
Nov-07-23 08:00AM	23andMe Launches Total Health , its Comprehensive, Prevention-Based Health Membership (GlobeNewswire)
Nov-06-23 08:00AM	23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 (GlobeNewswire)
Oct-31-23 08:00AM	23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data (GlobeNewswire) +9.70%
Oct-30-23 08:00AM	23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK (GlobeNewswire)
Oct-25-23 04:05PM	23andMe to Report FY2024 Second Quarter Financial Results (GlobeNewswire)
Oct-24-23 06:15PM	23andMe notifies customers of data breach into its 'DNA Relatives' feature (Reuters)
Oct-23-23 09:50AM	Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise (PR Newswire)

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HIBBS KATHY L	Chief Administrative Officer	May 02 '24	Option Exercise	0.42	38,551	16,191	1,290,866	May 06 04:56 PM
HIBBS KATHY L	Chief Administrative Officer	May 02 '24	Sale	0.49	38,551	19,048	1,252,315	May 06 04:56 PM
HIBBS KATHY L	Chief Administrative Officer	Apr 18 '24	Option Exercise	0.42	38,548	16,190	1,290,863	Apr 19 04:20 PM
HIBBS KATHY L	Chief Administrative Officer	Apr 18 '24	Sale	0.47	38,548	18,148	1,252,315	Apr 19 04:20 PM
HIBBS KATHY L	Chief Administrative Officer	Apr 04 '24	Option Exercise	0.42	38,548	16,190	1,290,863	Apr 05 04:14 PM
HIBBS KATHY L	Chief Administrative Officer	Apr 04 '24	Sale	0.50	38,548	19,282	1,252,315	Apr 05 04:14 PM
HIBBS KATHY L	Chief Administrative Officer	Mar 21 '24	Option Exercise	0.42	38,548	16,190	1,290,863	Mar 22 07:22 PM
HIBBS KATHY L	Chief Administrative Officer	Mar 21 '24	Sale	0.46	38,548	17,894	1,252,315	Mar 22 07:22 PM
HIBBS KATHY L	Chief Administrative Officer	Mar 07 '24	Option Exercise	0.42	38,548	16,190	1,290,863	Mar 11 04:09 PM
HIBBS KATHY L	Chief Administrative Officer	Mar 07 '24	Sale	0.53	38,548	20,430	1,252,315	Mar 11 04:09 PM
HIBBS KATHY L	Chief Administrative Officer	Feb 22 '24	Option Exercise	0.42	38,548	16,190	1,278,375	Feb 23 05:09 PM
HIBBS KATHY L	Chief Administrative Officer	Feb 22 '24	Sale	0.61	38,548	23,325	1,239,827	Feb 23 05:09 PM
HIBBS KATHY L	Chief Administrative Officer	Feb 15 '24	Option Exercise	0.42	38,548	16,190	1,318,897	Feb 16 04:47 PM
HIBBS KATHY L	Chief Administrative Officer	Feb 15 '24	Sale	0.78	38,548	30,210	1,280,349	Feb 16 04:47 PM
HIBBS KATHY L	Chief Administrative Officer	Jan 25 '24	Option Exercise	0.42	38,548	16,190	1,318,897	Jan 26 08:24 PM
HIBBS KATHY L	Chief Administrative Officer	Jan 25 '24	Sale	0.73	38,548	27,997	1,280,349	Jan 26 08:24 PM
HIBBS KATHY L	Chief Administrative Officer	Jan 11 '24	Option Exercise	0.42	38,548	16,190	1,318,897	Jan 12 06:51 PM
HIBBS KATHY L	Chief Administrative Officer	Jan 11 '24	Sale	0.72	38,548	27,581	1,280,349	Jan 12 06:51 PM
HIBBS KATHY L	Chief Administrative Officer	Dec 28 '23	Option Exercise	0.42	38,548	16,190	1,318,897	Dec 29 04:04 PM
HIBBS KATHY L	Chief Administrative Officer	Dec 28 '23	Sale	0.93	38,548	35,904	1,280,349	Dec 29 04:04 PM
HIBBS KATHY L	Chief Administrative Officer	Dec 14 '23	Option Exercise	0.42	38,548	16,190	1,318,897	Dec 18 04:17 PM
HIBBS KATHY L	Chief Administrative Officer	Dec 14 '23	Sale	0.97	38,548	37,222	1,280,349	Dec 18 04:17 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 30 '23	Option Exercise	0.42	38,548	16,190	1,318,897	Dec 01 04:22 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 30 '23	Sale	0.88	38,548	33,753	1,280,349	Dec 01 04:22 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 16 '23	Option Exercise	0.42	38,548	16,190	1,323,524	Nov 17 04:25 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 16 '23	Sale	0.77	38,548	29,732	1,284,976	Nov 17 04:25 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 02 '23	Option Exercise	0.42	38,548	16,190	1,323,524	Nov 03 07:02 PM
HIBBS KATHY L	Chief Administrative Officer	Nov 02 '23	Sale	0.87	38,548	33,437	1,284,976	Nov 03 07:02 PM
HIBBS KATHY L	Chief Administrative Officer	Oct 19 '23	Option Exercise	0.42	38,548	16,190	1,323,524	Oct 20 05:28 PM
HIBBS KATHY L	Chief Administrative Officer	Oct 19 '23	Sale	0.81	38,548	31,397	1,284,976	Oct 20 05:28 PM
HIBBS KATHY L	Chief Administrative Officer	Oct 05 '23	Option Exercise	0.42	38,548	16,190	1,323,524	Oct 06 05:16 PM
HIBBS KATHY L	Chief Administrative Officer	Oct 05 '23	Sale	0.84	38,548	32,407	1,284,976	Oct 06 05:16 PM
HIBBS KATHY L	Chief Administrative Officer	Sep 21 '23	Option Exercise	0.42	38,548	16,190	1,323,524	Sep 25 04:00 PM
HIBBS KATHY L	Chief Administrative Officer	Sep 21 '23	Sale	1.00	38,548	38,583	1,284,976	Sep 25 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ME

23andMe Holding Co

Upgrade your FINVIZ experience